Risk stratification system (CCCG-HB-2016)6
| Risk group | AFP (ng/mL) | PRETEXT staging system | COG staging system | Pathological type | P+/V+/M+/E+/H+/N+ | Note | |
| Very low risk | Stage I | Differentiated PFH | Both met simultaneously. | ||||
| Low risk | 1 | ≥100 | Stage I/II | None | All met simultaneously. | ||
| 2 | Stage I/II | Non-PFH and non-SUC | Both met simultaneously. | ||||
| Intermediate risk | 1 | Stage III | |||||
| 2 | Stage I/II | SUC | Both met simultaneously. | ||||
| 3 | Stage III | ||||||
| High risk | 1 | <100 | Satisfy any of them. | ||||
| 2 | Stage IV | ||||||
| 3 | Stage IV | ||||||
| 4 | P+/V+ | ||||||
AFP, alpha fetoprotein; CCCG-HB-2016, Chinese Anti-Cancer Association Pediatric Committee Hepatoblastoma consensus 2016; COG, Children’s Oncology Group; E+, extrahepatic and intra-abdominal diseases; H+, liver rupture or intraperitoneal bleeding; HB, hepatoblastoma; M+, instant metastasis; N+, lymph node involvement; P+, portal vein invasion; PFH, pure fetal histology; PRETEXT, PRE Treatment EXTent of disease; SUC, small cell undifferentiated; V+, inferior vena cava or hepatic vein invasion.